[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drugs in Development, 2021

March 2021 | 135 pages | ID: T6BB3F560D83EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drugs in Development, 2021

SUMMARY

According to the recently published report 'Tyrosine Protein Kinase SYK - Drugs in Development, 2021'; Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) pipeline Target constitutes close to 30 molecules.

Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Spleen tyrosine kinase, also known as Syk, is an enzyme encoded by the SYK gene. It regulates several biological processes including innate and adaptive immunity, cell adhesion, osteoclast maturation, platelet activation and vascular development. It assembles into signaling complexes with activated receptors at the plasma membrane via interaction between its SH2 domains and the receptor tyrosine-phosphorylated ITAM domains. The association with the receptor can also be indirect and mediated by adapter proteins containing ITAM or partial hemITAM domains. The phosphorylation of the ITAM domains is generally mediated by SRC subfamily kinases upon engagement of the receptor. More rarely signal transduction via SYK could be ITAM-independent.

The report 'Tyrosine Protein Kinase SYK - Drugs in Development, 2021' outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 2, 12 and 1 respectively.

Report covers products from therapy areas Immunology, Oncology, Ophthalmology, Hematological Disorders, Respiratory, Dermatology, Gastrointestinal, Central Nervous System, Infectious Disease and Musculoskeletal Disorders which include indications Rheumatoid Arthritis, Diffuse Large B-Cell Lymphoma, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Allergic Conjunctivitis, Atopic Dermatitis (Atopic Eczema), Mantle Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Ulcerative Colitis, Asthma, B-Cell Chronic Lymphocytic Leukemia, Follicular Lymphoma, Keratoconjunctivitis Sicca (Dry Eye), Kidney Transplant Rejection, Marginal Zone B-cell Lymphoma, Peripheral T-Cell Lymphomas (PTCL), Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acquired (Autoimmune) Hemolytic Anemia, Acute Lung Injury, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Respiratory Distress Syndrome, Allergies, Alopecia Areata, Alzheimer's Disease, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Chronic Cutaneous Lupus Erythematosus (CCLE)/Discoid Lupus Erythematosus (DLE), Chronic Obstructive Pulmonary Disease (COPD), Coronavirus Disease 2019 (COVID-19), Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Hand Dermatitis, Lung Cancer, Lupus Erythematosus, Lupus Nephritis, Multiple Sclerosis, Ocular Inflammation, Peritoneal Cancer, Pneumonia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma, Sicca Syndrome (Sjogren), Subacute Cutaneous Lupus Erythematosus (SCLE), Systemic Lupus Erythematosus, Unspecified Ophthalmological Disorders and Vitiligo.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Overview
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by AB Science SA, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Archer Pharmaceuticals Inc, 2021
Pipeline by Asana BioSciences LLC, 2021
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, 2021
Pipeline by Clevexel Pharma SA, 2021
Pipeline by Genosco Inc, 2021
Pipeline by GlaxoSmithKline Plc, 2021
Pipeline by Hanmi Pharmaceuticals Co Ltd, 2021
Pipeline by Hutchison MediPharma Ltd, 2021
Pipeline by IACTA Pharmaceuticals Inc, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Kronos Bio Inc, 2021
Pipeline by Levolta Pharmaceuticals Inc, 2021
Pipeline by Millennium Pharmaceuticals Inc, 2021
Pipeline by Nano Biotherapeutics Inc, 2021
Pipeline by Origenis GmbH, 2021
Pipeline by Pulmatrix Inc, 2021
Pipeline by Rigel Pharmaceuticals Inc, 2021
Pipeline by Taiho Pharmaceutical Co Ltd, 2021
Pipeline by TopiVert Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Dormant Products, 2021 (Contd..4)
Dormant Products, 2021 (Contd..5)
Discontinued Products, 2021
Discontinued Products, 2021 (Contd..1)

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Type, 2021


More Publications